Literature DB >> 15249179

Stunned peri-infarct canine myocardium is characterized by degradation of troponin T, not troponin I.

David A Colantonio1, Jennifer E Van Eyk, Karin Przyklenk.   

Abstract

OBJECTIVE: Degradation of cardiac troponin I (cTnI) has been proposed to represent the underlying molecular mechanism responsible for post-ischemic contractile dysfunction of viable but 'stunned' myocardium. However, this concept is largely derived from models of brief, sublethal ischemia essentially devoid of necrosis, and there is speculation that defects in cTnI may be model-dependent. Accordingly, our primary aim was to evaluate the integrity of cardiac troponins-i.e., cTnI, as well as cTnT and cTnC-in viable but stunned peri-infarct tissue. In addition, we addressed the as-yet unexplored issue of whether the profound reduction of infarct size evoked by brief preconditioning ischemia (PC) was accompanied by a favorable attenuation in ischemia/reperfusion-induced degradation of cTnI, cTnT or cTnC in the remaining viable subepicardium.
METHODS: Anesthetized open-chest dogs received 10 min of PC ischemia or a comparable control period, followed by 1 h of sustained coronary occlusion and 3 h of reperfusion. Subepicardial biopsies from the center of the soon-to-be ischemic territory were obtained at baseline and at 30 min and 3 h post-reflow, and myofilament protein integrity (intact cTnI, cTnT and cTnC, as well as degradation bands and covalent complexes) were assessed by Western immunoblotting. In addition, in all dogs, wall thickening was measured by echocardiography, collateral blood flow was assessed during sustained occlusion by injection of radiolabeled microspheres, and infarct size was delineated by tetrazolium staining.
RESULTS: Although PC was, as expected, cardioprotective (infarct size of 2 +/- 1% of the risk region vs. 17 +/- 6% in controls; p < 0.05), both control and PC groups exhibited profound and comparable contractile dysfunction following reflow (mean wall thickening reduced to 20-22% of baseline values). There was, however, no significant degradation of cTnI in the viable but stunned, peri-infarct tissue. We did observe degradation of cTnT in the stunned subepicardium, an effect that was attenuated in dogs that received antecedent PC ischemia. However, there was no correlation between post-ischemic wall thickening and the immunoreactivity of the intact cTnT band, or wall thickening and the intensity of the cTnT degradation products.
CONCLUSIONS: Our results suggest cTnI degradation is not a universal determinant of post-ischemic myocardial stunning. Moreover, the dissociation between cTnT degradation and wall thickening argue against a direct 'cause-and-effect' relationship between proteolysis of cTnT and acute, post-ischemic contractile dysfunction of stunned peri-infarct myocardium. Copyright 2004 European Society of Cardiology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249179     DOI: 10.1016/j.cardiores.2004.04.006

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  11 in total

1.  Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure.

Authors:  Jiang Zhang; Moltu J Guy; Holly S Norman; Yi-Chen Chen; Qingge Xu; Xintong Dong; Huseyin Guner; Sijian Wang; Takushi Kohmoto; Ken H Young; Richard L Moss; Ying Ge
Journal:  J Proteome Res       Date:  2011-07-28       Impact factor: 4.466

Review 2.  Functional consequences of sarcomeric protein abnormalities in failing myocardium.

Authors:  Martin M LeWinter
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.214

3.  Why does troponin I have so many phosphorylation sites? Fact and fancy.

Authors:  R John Solaro; Jolanda van der Velden
Journal:  J Mol Cell Cardiol       Date:  2010-02-25       Impact factor: 5.000

4.  Profound cardioprotection with chloramphenicol succinate in the swine model of myocardial ischemia-reperfusion injury.

Authors:  Javier A Sala-Mercado; Joseph Wider; Vishnu Vardhan Reddy Undyala; Salik Jahania; Wonsuk Yoo; Robert M Mentzer; Roberta A Gottlieb; Karin Przyklenk
Journal:  Circulation       Date:  2010-09-14       Impact factor: 29.690

5.  Selective deletion of the NH2-terminal variable region of cardiac troponin T in ischemia reperfusion by myofibril-associated mu-calpain cleavage.

Authors:  Zhiling Zhang; Brandon J Biesiadecki; Jian-Ping Jin
Journal:  Biochemistry       Date:  2006-09-26       Impact factor: 3.162

6.  In vivo phosphorylation site mapping in mouse cardiac troponin I by high resolution top-down electron capture dissociation mass spectrometry: Ser22/23 are the only sites basally phosphorylated.

Authors:  Serife Ayaz-Guner; Jiang Zhang; Lin Li; Jeffery W Walker; Ying Ge
Journal:  Biochemistry       Date:  2009-09-01       Impact factor: 3.162

7.  Calpain inhibition attenuates right ventricular contractile dysfunction after acute pressure overload.

Authors:  Clifford R Greyson; Gregory G Schwartz; Li Lu; Shuyu Ye; Steve Helmke; Ya Xu; Hasan Ahmad
Journal:  J Mol Cell Cardiol       Date:  2007-10-23       Impact factor: 5.000

Review 8.  Cardiovascular proteomics: past, present, and future.

Authors:  Melanie Y White; Jennifer E Van Eyk
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  Increased cross-bridge cycling kinetics after exchange of C-terminal truncated troponin I in skinned rat cardiac muscle.

Authors:  Kittipong Tachampa; Tomoyoshi Kobayashi; Helen Wang; Anne F Martin; Brandon J Biesiadecki; R John Solaro; Pieter P de Tombe
Journal:  J Biol Chem       Date:  2008-03-31       Impact factor: 5.157

10.  Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension.

Authors:  Hasan A Ahmad; Li Lu; Shuyu Ye; Gregory G Schwartz; Clifford R Greyson
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05-10       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.